Combo vaccine production is cut

Article

Manufacturing problems have cut production of a four-disease combination vaccine (Pro Quad) made by Merck (MMWR Wkly Rept:56(18);45), according to the Centers for Disease Control and Prevention (CDC). The vaccine protects against measles, mumps, rubella, and varicella. [more].

Manufacturing problems have cut production of a four-disease combination vaccine (Pro Quad) made by Merck (MMWR Wkly Rept:56(18);45), according to the Centers for Disease Control and Prevention (CDC). The vaccine protects against measles, mumps, rubella, and varicella. [more].

Current projections of orders show that ProQuad will be unavailable beginning in July 2007, which might cause extended back orders for the next few months. After the existing supply is depleted, the vaccine will not be available for the remainder of 2007.

The company is asking customers to begin using its combined measles, mumps, and rubella vaccine, (M-M-RII) and varicella vaccine (Varivax) as soon as possible. Merck expects to be able to meet the demand for these two vaccines for all age groups, including the routine two-dose schedule for children ages 12 to 15 months and 4 to 6 years, catch-up vaccination for the second dose for children and adolescents who received only one dose, and vaccination with two doses for other children, adolescents, and adults.

For questions regarding supply of these products, contact Merck’s National Service Center at 800-637-2590.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.